BIOMARIN PHARMACEUTICAL INC (1BMRN.MI) Stock Price, Quote, News and Overview
BIT:1BMRN - Euronext Milan - US09061G1013 - Common Stock - Currency: EUR
1BMRN.MI Quote, Performance and Key Statistics
BIT:1BMRN (5/19/2025, 7:00:00 PM)
52.36
-9.36 (-15.17%)
The current stock price of 1BMRN.MI is 52.36 EUR.
1BMRN.MI Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| 4AB.DE | ABBVIE INC | 17.88 | 286.51B | ||
| AMG.DE | AMGEN INC | 13.57 | 133.86B | ||
| GIS.DE | GILEAD SCIENCES INC | 13.98 | 118.91B | ||
| VX1.DE | VERTEX PHARMACEUTICALS INC | N/A | 102.00B | ||
| 1REGN.MI | REGENERON PHARMACEUTICALS | 13.77 | 58.22B | ||
| ARGX.BR | ARGENX SE | 108.46 | 31.32B | ||
| 22UA.DE | BIONTECH SE-ADR | N/A | 21.05B | ||
| IDP.DE | BIOGEN INC | 8.2 | 16.80B | ||
| 0QF.DE | MODERNA INC | N/A | 9.23B | ||
| 1MRNA.MI | MODERNA INC | N/A | 9.15B | ||
| BIO.DE | BIOTEST AG | 65.85 | 1.69B | ||
| GLPG.AS | GALAPAGOS NV | N/A | 1.69B |
Related stock screener links
About 1BMRN.MI
Company Profile
BioMarin Pharmaceutical, Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. The company is headquartered in Novato, California and currently employs 3,401 full-time employees. BioMarin's commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Voxzogo is a once daily injection analog of C-type Natriuretic Peptide (CNP) for the treatment of achondroplasia. Brineura is a recombinant human tripeptidyl peptidase 1 (TPP1) for the treatment of patients with CLN2, a form of Batten disease.
Company Info
BIOMARIN PHARMACEUTICAL INC
105 Digital Drive
Novato CALIFORNIA US
Employees: 3401
Phone: 14155056700
BIOMARIN PHARMACEUTICAL INC / 1BMRN.MI FAQ
What is the stock price of BIOMARIN PHARMACEUTICAL INC today?
The current stock price of 1BMRN.MI is 52.36 EUR. The price decreased by -15.17% in the last trading session.
What is the ticker symbol for BIOMARIN PHARMACEUTICAL INC stock?
The exchange symbol of BIOMARIN PHARMACEUTICAL INC is 1BMRN and it is listed on the Euronext Milan exchange.
On which exchange is 1BMRN.MI stock listed?
1BMRN.MI stock is listed on the Euronext Milan exchange.
What is the price forecast or stock price prediction for BIOMARIN PHARMACEUTICAL INC stock?
35 analysts have analysed 1BMRN.MI and the average price target is 93.14 EUR. This implies a price increase of 77.88% is expected in the next year compared to the current price of 52.36. Check the BIOMARIN PHARMACEUTICAL INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is BIOMARIN PHARMACEUTICAL INC worth?
BIOMARIN PHARMACEUTICAL INC (1BMRN.MI) has a market capitalization of 9.98B EUR. This makes 1BMRN.MI a Mid Cap stock.
How many employees does BIOMARIN PHARMACEUTICAL INC have?
BIOMARIN PHARMACEUTICAL INC (1BMRN.MI) currently has 3401 employees.
Is BIOMARIN PHARMACEUTICAL INC (1BMRN.MI) expected to grow?
The Revenue of BIOMARIN PHARMACEUTICAL INC (1BMRN.MI) is expected to grow by 17.05% in the next year. Check the estimates tab for more information on the 1BMRN.MI EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy BIOMARIN PHARMACEUTICAL INC (1BMRN.MI) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of 1BMRN.MI, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of 1BMRN.MI, evaluating the profitability, health, valuation and growth aspects
- BIOMARIN PHARMACEUTICAL INC (1BMRN.MI) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- BIOMARIN PHARMACEUTICAL INC (1BMRN.MI) Sales and EPS estimates to see what analysts future expectations are.
- BIOMARIN PHARMACEUTICAL INC (1BMRN.MI) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- BIOMARIN PHARMACEUTICAL INC (1BMRN.MI) Insider and Institutional Ownership to learn about the owners and their transactions.
- BIOMARIN PHARMACEUTICAL INC (1BMRN.MI) Stock Chart to make your own analysis
- BIOMARIN PHARMACEUTICAL INC (1BMRN.MI) Latest news and press-releases to stay up to date.
Does BIOMARIN PHARMACEUTICAL INC (1BMRN.MI) stock pay dividends?
1BMRN.MI does not pay a dividend.
When does BIOMARIN PHARMACEUTICAL INC (1BMRN.MI) report earnings?
BIOMARIN PHARMACEUTICAL INC (1BMRN.MI) will report earnings on 2025-02-20, after the market close.
What is the Price/Earnings (PE) ratio of BIOMARIN PHARMACEUTICAL INC (1BMRN.MI)?
The PE ratio for BIOMARIN PHARMACEUTICAL INC (1BMRN.MI) is 33.78. This is based on the reported non-GAAP earnings per share of 1.55 and the current share price of 52.36 EUR. Check the full fundamental report for a full analysis of the valuation metrics for 1BMRN.MI.
1BMRN.MI Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to 1BMRN.MI.
1BMRN.MI Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to 1BMRN.MI. 1BMRN.MI is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average.
1BMRN.MI Financial Highlights
Over the last trailing twelve months 1BMRN.MI reported a non-GAAP Earnings per Share(EPS) of 1.55. The EPS increased by 127.27% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 11.71% | ||
| ROA | 4.7% | ||
| ROE | 5.95% | ||
| Debt/Equity | 0.11 |
1BMRN.MI Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 79% to 1BMRN.MI. The Buy consensus is the average rating of analysts ratings from 35 analysts.
For the next year, analysts expect an EPS growth of 120.5% and a revenue growth 17.05% for 1BMRN.MI